Skip to main content
IMS Events Main banner
Rate ePoster

    Cellular and T cell engager Immunotherapy

    Category: Cellular and T cell engager Immunotherapy

    Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    (PA-061) Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Friday, September 19, 2025
    Introduction: Talquetamab (Tal) is the first G protein–coupled receptor class C group 5 member D-targeting bispecific antibody approved for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) based on results from the MonumenTAL-1 study (NCT03399799/NCT04634552). The nationwide Flatiron Health database is a collection of clinical data derived from deidentified electronic health records that characterizes real-world physician’s choice of treatment (RWPC) in patients (pts) with TCE RRMM. Previous indirect comparisons showed superior efficacy outcomes with Tal vs RWPC in pts with TCE RRMM. We report an updated adjusted comparison of Tal vs RWPC in pts with TCE RRMM with longer follow-up in the MonumenTAL-1 study.

    Methods: Individual pt-level data from MonumenTAL-1 were included for pts who received subcutaneous Tal 0.4 mg/kg weekly (QW; n=143) or 0.8 mg/kg every other week (Q2W; n=154) using a data cut-off of September 2024; median follow-up was 38.2 (QW) and 31.2 (Q2W) months. An external control arm was created from the deidentified database (as of October 2024) for pts who met key MonumenTAL-1 eligibility criteria (N=629 with 1169 eligible lines of therapy). A base case and fully adjusted model adjusted for baseline prognostic variables using inverse probability of treatment weighting. Baseline covariate balance after adjustment was assessed using standardized mean differences (SMDs). Outcomes assessed were progression-free survival (PFS), overall survival (OS), and time to next treatment (TTNT). A weighted Cox proportional hazards model estimated hazard ratios (HRs) and 95% CIs, and a weighted Kaplan-Meier method estimated median time-to-event outcomes. Sensitivity analyses evaluated the impact of alternative statistical methods and variable adjustment.

    Results: After reweighting, baseline characteristics were balanced between the RWPC and Tal cohorts, with all SMDs < 0.1. In the base case model, pts receiving Tal QW had significantly superior outcomes vs RWPC, with longer PFS (HR 0.66 [95% CI 0.53–0.82]; P< 0.001; median 7.5 vs 4.8 months), longer OS (HR 0.56 [0.42–0.74]; P< 0.001; median 34.0 vs 16.5 months), and longer TTNT (HR 0.57 [0.47–0.69]; P< 0.001; median 9.1 vs 5.1 months). Similarly, pts receiving Tal Q2W had significantly superior outcomes vs RWPC, with longer PFS (HR 0.54 [0.44–0.68]; P< 0.001; median 11.2 vs 4.7 months), longer OS (HR 0.42 [0.31–0.57]; P< 0.001; median not reached vs 15.8 months), and longer TTNT (HR 0.49 [0.40–0.60]; P< 0.001; median 11.8 vs 5.1 months). Results were generally consistent in the full model and across sensitivity analyses.

    Conclusions: Results from the MonumenTAL-1 study continued to demonstrate superior effectiveness of Tal, especially with the Q2W dosing schedule vs RWPC, highlighting its clinical benefit and further supporting Tal as a compelling treatment for pts with TCE RRMM.